Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
NEW YORK, Oct. 27, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
http://www.reportlinker.com/p0336639/Attention-Deficit-Hyperactivity-Disorder-ADHD-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Summary
GlobalData, the industry analysis specialist, has released its new report, "Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global ADHD market. The report identifies the key trends shaping and driving the global ADHD market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global ADHD sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
GlobalData estimates that the global ADHD therapeutics market was valued at $3855.6m in 2010, and is forecast to grow at a compound annual growth rate (CAGR) of 8.0% over the next eight years, to reach $7114.5m by 2018. Between 2005 and 2010, three drugs namely Daytrana (methylphenidate), Vyvanse (lisdexamfetamine) and Intuniv (guanfacine) were approved in the US. The acceptance for Vyvanse was high in the US, in spite of its high treatment cost in comparison to that of existing drugs. Thus, high acceptance for Vyvanse has resulted in the significant growth of the market. In 2009, the authorized generic versions of Adderall XR (mixed amphetamine salt) were launched, due to which the US market declined. This has resulted in the decline in the global ADHD market in 2009.
Between 2010 and 2018, the global ADHD market is expected to grow at a CAGR of 8%. The growth rate is similar across the US and European countries, but it is slightly high in Japan (18.4%). This difference across geographical markets exists because of the variation in the approval date for some of the drugs in the US, Europe and Japan. In the US, major nonstimulant therapies such as Vyvanse, Intuniv and Kapvay (clonidine hydrochloride) are already approved; whereas these drugs are not approved in Europe and Japan. The entry of Vyvanse and Intuniv in major European markets is expected in 2012 and 2014 respectively. Vyvanse, being a safer nonstimulant, its acceptance across Europe would be high and considered as growth driving factor for the European ADHD market. The other drugs which are expected to enter into the market during the forecast period such as NWP06, CM4612 and RIT124D have similar therapeutic mode of action as that of exiting drugs which will not impact the market significantly.
During this forecast period, patents for various drugs such as Adderall XR, Daytrana, Concerta (methylphenidate), Strattera (atomoxetine) and Kapvay are set to expire. However, the losses due to expiry of these patents would be compensated by new drugs entering the market such as Vyvanse and Intuniv. Thus, the global ADHD market will show a steady growth from 2010 to 2018.
Note: This is a on-demand report and will be delivered within 3 business days of the purchase (excluding weekends).
Scope
The report provides information on the key drivers and challenges of the ADHD market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) ADHD market revenues data from 2005 to 2010, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as norepinephrine-dopamine reuptake inhibitor, selective alpha2A-adrenergic receptor agonist, serotonin-norepinephrine-dopamine reuptake inhibitor, selective serotonin (5-HT1)-dopamine antagonist, serotonin (5-HT1A and 5-HT1B) receptor agonists, highly selective norepinephrine reuptake inhibitor (NRI), antagonist of alcohol-metabolic effects, dopamine partial agonist, alpha 4 beta 2 neuronal nicotinic receptor (NNR) agonists, dopamine antagonist, alpha7 NNR agonist., serotonin and norepinephrine reuptake inhibitor, selective serotonin reuptake inhibitors (SSRIs), dopamine (D2) receptors and serotonin type 2 (5-HT2) receptor agonist, alpha 3 beta 2 and alpha 4 beta 2 NNR antagonist, histamine H3 receptor antagonist, selective alpha2A-adrenergic receptor agonist, histamine H3 autoreceptor antagonist, ?-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptor modulators, specific phosphodiesterase 1 (PDE1) inhibitor, dopamine uptake inhibitors and serotonin (5-HT6) receptor antagonist.
- Analysis of the current and future competition in the global ADHD market. Key market players covered are Curemark LLC, Johnson & Johnson, Nextwave Pharmaceuticals, Novartis AG and Shire Plc.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the ADHD therapeutics market.
- Analysis of key recent licensing and partnership agreements in ADHD market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global ADHD market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global ADHD market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global ADHD market landscape? – Identify, understand and capitalize.
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 7
1.2 List of Figures 9
2 Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics: Executive Summary 11
2.1 ADHD Therapeutics Market is Forecast to Show Steady Growth Until 2018 11
2.2 Shire Remains the Unchallenged Leader of the ADHD Market 12
2.3 Current Medications Partly serve the ADHD Therapeutics Market 13
2.4 Expected Launch of New Molecules will Intensify Competition in the ADHD Market 14
2.5 Adult ADHD Market Presents Opportunity 14
3 Attention Deficit Hyperactivity Disorder (ADHD): Introduction 15
3.1 Disease Overview 15
3.2 Epidemiology 16
3.2.1 Prevalence/Incidence 16
3.2.2 Quality of Life (Qol) 18
3.2.3 Pharmacoeconomic Burden: 19
3.3 Etiology and Pathophysiology 20
3.3.1 Genetic Causes 20
3.3.2 Environmental Causes 21
3.4 Signs and Symptoms 22
3.4.1 Symptoms for Inattention 22
3.4.2 Symptoms for Hyperactivity 22
3.4.3 Symptoms for Impulsivity 22
3.5 Diagnosis 23
3.5.1 Diagnostic Criteria for ADHD 24
3.5.2 Rating Scales Used for the Diagnosis: 26
3.6 Treatment and Management Options 30
3.6.1 Pharmacologic Treatment: 31
3.6.2 Behavioral therapy 32
3.7 Referral Pathway 33
3.8 GlobalData Pipeline Report Guidance 35
4 ADHD Therapeutics: Market Characterization 36
4.1 ADHD Therapeutics Market Size (2005–2010) – Global 36
4.2 ADHD Therapeutics Market Forecast (2010–2018) – Global 37
4.3 ADHD Therapeutics Market Size (2005–2010) – The US 39
4.4 ADHD Therapeutics Market Forecast (2010–2018) – The US 40
4.5 ADHD Therapeutics Market Size (2005–2010) – France 41
4.6 ADHD Therapeutics Market Forecast (2010–2018) – France 43
4.7 ADHD Therapeutics Market Size (2005–2010) – Germany 44
4.8 ADHD Therapeutics Market Forecast (2010–2018) – Germany 45
4.9 ADHD Therapeutics Market Size (2005–2010) – Italy 47
4.10 ADHD Therapeutics Market Forecast (2010–2018) – Italy 48
4.11 ADHD Therapeutics Market Size (2005–2010) – Spain 50
4.12 ADHD Therapeutics Market Forecast (2010–2018) – Spain 51
4.13 ADHD Therapeutics Market Size (2005–2010) – The UK 52
4.14 ADHD Therapeutics Market Forecast (2010–2018) – The UK 53
4.15 ADHD Therapeutics Market Size (2005–2010) – Japan 55
4.16 ADHD Therapeutics Market Forecast (2010–2018) – Japan 56
4.17 Drivers and Barriers for the ADHD Therapeutics Market 58
4.17.1 Drivers for the ADHD Therapeutics Market 58
4.17.2 Barriers for the ADHD Therapeutics Market 58
4.18 Opportunity and Unmet Need Analysis 60
4.19 Key Takeaway 62
5 ADHD Therapeutics: Competitive Assessment 63
5.1 Overview 63
5.2 Strategic Competitor Assessment 63
5.3 Product Profiles for the Major Marketed Products in the ADHD Therapeutics Market 64
5.3.1 Ritalin LA (methylphenidate hydrochloride long acting capsules) 64
5.3.2 Adderall XR (Mixed amphetamine salt) 65
5.3.3 Daytrana (methylphenidate transdermal system) 68
5.3.4 Vyvanse (lisdexamfetamine dimesylate) 70
5.3.5 Concerta (methylphenidate hydrochloride) 73
5.3.6 Strattera (atomoxetine hydrochloride) 76
5.3.7 Intuniv (guanfacine) 78
5.3.8 Kapvay (clonidine hydrochloride) 80
5.4 Key Takeaway 82
6 ADHD Therapeutics: Pipeline Assessment 83
6.1 Overview 83
6.2 Strategic Pipeline Assessment 83
6.3 ADHD Therapeutics Pipeline – Pipeline by Phases of Development 84
6.3.1 ADHD Therapeutics – Filed Pipeline 84
6.3.2 ADHD Therapeutics – Phase III Pipeline 84
6.3.3 ADHD Therapeutics – Phase II/III Pipeline 85
6.3.4 ADHD Therapeutics – Phase II Pipeline 85
6.3.5 ADHD Therapeutics – Phase I Pipeline 86
6.3.6 ADHD Therapeutics – Pre-Clinical Pipeline 86
6.3.7 Technology Trends Analytic Framework 87
6.4 ADHD Therapeutics Market –Clinical Pipeline by Mechanism of Action 89
6.5 ADHD Therapeutics – Promising Drugs under Clinical Development 90
6.6 Molecule Profile for Promising Drug Under Clinical Development 91
6.6.1 NWP06 91
6.6.2 CM-4612 91
6.6.3 RIT124D 91
6.6.4 JNS001 91
6.7 Key Takeaway 91
7 ADHD Therapeutics: Clinical Trials Mapping 92
7.1 Clinical Trials by Region/Country (The US, EU5 and Japan) 92
7.2 Clinical Trials by Phase 93
7.3 Clinical Trials by Trial Status 95
7.4 Prominent Sponsors 96
7.5 Top Companies Participating in ADHD Therapeutics Clinical Trials 98
8 Strategic Assessment 100
8.1 Key Events Impacting the Future Market 100
8.2 ADHD Therapeutics: Implications for Future Market Competition 101
9 ADHD Therapeutics: Future Players 103
9.1 Introduction 103
9.2 Company Profiles 104
9.2.1 Curemark, LLC. 104
9.2.2 Johnson & Johnson 104
9.2.3 NextWave Pharmaceuticals 107
9.2.4 Novartis AG 108
9.2.5 Shire Plc. 110
9.2.6 Other Companies in the ADHD Therapeutics Market 112
10 ADHD Therapeutics: Licensing and Partnership Deals 116
11 ADHD Therapeutics: Appendix 119
11.1 Market Definitions 119
11.2 Abbreviations 119
11.3 Methodology 121
11.3.1 Coverage 121
11.3.2 Secondary Research 121
11.3.3 Forecasting 122
11.3.4 Primary Research 124
11.3.5 Expert Panel Validation 125
11.4 Contact Us 125
11.5 Disclaimer 125
11.6 Bibliography 126
List of Tables
Table 1: ADHD Therapeutics- Comorbidities 16
Table 2: Prevalence of subtypes of ADHD as per KiGGS 18
Table 3: Common Assessment Scales used to aid the diagnosis of ADHD 27
Table 4: Rating Scales used for the diagnosis of childhood, adolescent and adult ADHD 29
Table 5: Drugs commonly prescribed for ADHD 31
Table 6: ADHD Therapeutics Market, Global, Revenue ($m), 2005–2010 37
Table 7: ADHD Therapeutics Market, Global, Forecasts ($m), 2010–2018 39
Table 8: ADHD Therapeutics Market, The US, Revenue ($m), 2005–2010 40
Table 9: ADHD Therapeutics Market, The US, Forecasts ($m), 2010–2018 41
Table 10: ADHD Therapeutics Market, France, Revenue ($m), 2005–2010 42
Table 11: ADHD Therapeutics Market, France, Forecasts ($m), 2010–2018 44
Table 12: ADHD Therapeutics Market, Germany, Revenue ($m), 2005–2010 45
Table 13: ADHD Therapeutics Market, Germany, Forecasts ($m), 2010–2018 47
Table 14: ADHD Therapeutics Market, Italy, Revenue ($m), 2005–2010 48
Table 15: ADHD Therapeutics Market, Italy, Forecasts ($m), 2010–2018 49
Table 16: ADHD Therapeutics Market, Spain, Revenue ($m), 2005–2010 51
Table 17: ADHD Therapeutics Market, Spain, Forecasts ($m), 2010–2018 52
Table 18: ADHD Therapeutics Market, Spain, Revenue ($m), 2005–2010 53
Table 19: ADHD Therapeutics Market, The UK, Forecasts ($m), 2010–2018 55
Table 20: ADHD Therapeutics Market, Japan, Revenue ($m), 2005–2010 56
Table 21: ADHD Therapeutics Market, Japan, Forecasts ($m), 2010–2018 57
Table 22: Adverse Events Associated with Adderall XR 67
Table 23: Clinical Studies for Adderall XR 67
Table 24: Adverse Events Associate with Daytrana 69
Table 25: Clinical Studies for Daytrana 70
Table 26: ADHD Therapeutics- Adverse Events Associated with Vyvanse 72
Table 27: Clinical Studies for Vyvanse 73
Table 28: Common Treatment Emergent Adverse Events Associated with Concerta 75
Table 29: Clinical Studies for Concerta 76
Table 30: Common Treatment Emergent Adverse Events Associated with Strattera 77
Table 31: Clinical Studies for Strattera 78
Table 32: Common treatment Emergent Adverse Events Associated with Intuniv 79
Table 33: Clinical Studies for Intuniv 80
Table 34: Common Adverse Events Associated with Kapvay in Children and Adolescents 81
Table 35: Clinical Studies for Kapvay 81
Table 36: ADHD Therapeutics, Filed Pipeline, 2011 84
Table 37: ADHD Therapeutics, Phase III Pipeline, 2011 85
Table 38: ADHD Therapeutics, Phase II/III Pipeline, 2011 85
Table 39: ADHD Therapeutics, Phase II Pipeline, 2011 85
Table 40: ADHD Therapeutics, Phase I Pipeline, 2011 86
Table 41: ADHD Therapeutics, Pre-Clinical Pipeline, 2011 86
Table 42: ADHD Therapeutics, Most Promising Drugs Under Clinical Development, 2011 90
Table 43: ADHD Therapeutics, Clinical Trials by Country, 2011 93
Table 44: ADHD Therapeutics - Clinical Trials by Phase, 2011 94
Table 45: ADHD Therapeutics, Clinical Trials by Status (%), 2011 95
Table 46: ADHD Therapeutics, Prominent Sponsors, 2011 97
Table 47: ADHD Therapeutics, Top Companies Participating in Clinical Trials, 2011 98
Table 48: Curemark LLC., ADHD Pipeline, 2011 104
Table 49: Curemark LLC., CNS Pipeline, 2011 104
Table 50: Johnson & Johnson, ADHD Pipeline, 2011 106
Table 51: Johnson & Johnson, CNS Pipeline, 2011 107
Table 52: NextWave Pharmaceuticals, ADHD Pipeline, 2011 107
Table 53: NextWave Pharmaceuticals, CNS Pipeline, 2011 107
Table 54: Novartis ADHD Pipeline, 2011 110
Table 55: Novartis, CNS Pipeline, 2011 110
Table 56: Shire Plc., ADHD Pipeline, 2011 112
Table 57: Shire Plc., CNS Pipeline, 2011 112
Table 58: ADHD Therapeutics Market, Future Players 112
Table 59: ADHD Therapeutics, Global, Deals, 2009-2011 116
List of Figures
Figure 1: ADHD Therapeutics Market, Global, Revenue and Forecasts ($m), 2005–2018 11
Figure 2: Opportunity and Unmet Need in the ADHD Therapeutics Market, 2010 13
Figure 3: A three-dimensional, high-resolution MRI image of the brain of a patient with ADHD 21
Figure 4: ADHD Therapeutics – Diagnosis Of ADHD 23
Figure 5: ADHD Therapeutics – Barkley Home Situations Questionnaire (HSQ) 28
Figure 6: ADHD Therapeutics - Adult Self Report Scale VI.I (ASRS-VI.I) Screener 30
Figure 7: ADHD Therapeutics - Referral Pathway 33
Figure 8: ADHD Therapeutics Market, Global, Revenue ($m), 2005–2010 36
Figure 9: ADHD Therapeutics Market, Global, Forecast ($m), 2010–2018 38
Figure 10: ADHD Therapeutics Market, The US, Revenue ($m), 2005–2010 39
Figure 11: ADHD Therapeutics Market, The US, Forecast ($m), 2010–2018 41
Figure 12: ADHD Therapeutics Market, France, Revenue ($m), 2005–2010 42
Figure 13: ADHD Therapeutics Market, France, Forecast ($m), 2010–2018 43
Figure 14: ADHD Therapeutics Market, Germany, Revenue ($m), 2005–2010 44
Figure 15: ADHD Therapeutics Market, Germany, Forecast ($m), 2010–2018 46
Figure 16: ADHD Therapeutics Market, Italy, Revenue ($m), 2005–2010 47
Figure 17: ADHD Therapeutics Market, Italy, Forecast ($m), 2010–2018 49
Figure 18: ADHD Therapeutics Market, Spain, Revenue ($m), 2005–2010 50
Figure 19: ADHD Therapeutics Market, Spain, Forecast ($m), 2010–2018 51
Figure 20: ADHD Therapeutics Market, The UK, Revenue ($m), 2005–2010 53
Figure 21: ADHD Therapeutics Market, The UK, Forecast ($m), 2010–2018 54
Figure 22: ADHD Therapeutics Market, Japan, Revenue ($m), 2005–2010 55
Figure 23: ADHD Therapeutics Market, Japan, Forecast ($m), 2010–2018 57
Figure 24: Opportunity and Unmet Need in the ADHD Therapeutics Market, 2010 60
Figure 25: ADHD Therapeutics, Strategic Competitor Assessment, 2010 64
Figure 26: ADHD Therapeutics – Pipeline by Phase of Development, 2011 84
Figure 27: ADHD Therapeutics, Technology Trends Analytics Framework, 2011 87
Figure 28: ADHD Therapeutics, Technology Trends Analytics Framework, Description, 2011 89
Figure 29: ADHD Therapeutics, Pipeline by Mechanism of Action (%), 2011 90
Figure 30: ADHD Therapeutics - Clinical Trials by Country, 2011 92
Figure 31: ADHD Therapeutics, Clinical Trials by Phase (%), 2011 93
Figure 32: ADHD Therapeutics, Clinical Trials by Status (%), 2011 95
Figure 33: ADHD Therapeutics, Overall sponsors (%), 2011 96
Figure 34: ADHD Therapeutics, Prominent Sponsors (%), 2011 97
Figure 35: ADHD Therapeutics, Top Companies Participating in Clinical Trials, 2011 98
Figure 36: ADHD Therapeutics Market, Drivers and Restraints, 2011 100
Figure 37: Implications for Future Market Competition in the ADHD Market, 2011 101
Figure 38: ADHD Therapeutics Market, Pipeline by Company, 2011 103
Figure 39: GlobalData Market Forecasting Model 124Curemark, LLC.
Johnson & Johnson
NextWave Pharmaceuticals
Novartis AG
Shire Plc.
To order this report:
Pathology Industry: Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Pathology Business News
Check our Industry Analysis and Insights
CONTACT
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article